

APC/Cyanine7 anti-human CD3 Antibody

Catalog# / Size	300317 / 25 tests 300318 / 100 tests
Clone	HIT3a
Regulatory Status	RUO
Workshop	V CD03.05
Other Names	T3, CD3ε
Isotype	Mouse IgG2a, κ
Description	CD3ε is a 20 kD chain of the CD3/T-cell receptor (TCR) complex which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T-cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK-T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details

Verified Reactivity	Human
Antibody Type	Monoclonal
Host Species	Mouse
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation	The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration	Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The CD3 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser	Red Laser (633 nm)
Application Notes	Additional reported (for the relevant formats) applications include: immunohistochemical staining of acetone-fixed frozen sections, immunoprecipitation, and activation of T lymphocytes ⁴⁻⁷ . The HIT3a antibody is able to stimulate T cell activation. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300314). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 300332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional Product Notes	BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References	<ol style="list-style-type: none"> Schlossman S, <i>et al.</i> Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York. Barclay N, <i>et al.</i> 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego. Sedelies KA, <i>et al.</i> 2004. <i>J. Biol. Chem.</i> 279:26581. (Activ) Rivollier A, <i>et al.</i> 2004. <i>Blood</i> 104:4029. (Activ) Scharschmidt E, <i>et al.</i> 2004. <i>Mol. Cell Biol.</i> 24:3860. (Activ) Smeltz RB. 2007. <i>J. Immunol.</i> 178:4786. (Activ) Ohue Y, <i>et al.</i> 2014. <i>Clin Cancer Res.</i> 20:5052. PubMed
(PubMed link indicates BioLegend citation)	

9. Sato K, *et al.* 2014. *PLoS Pathog.* 10:1004453. [PubMed](#)
10. Luetke-Eversloh M, *et al.* 2014. *PLoS Pathog.* 10:1004441. [PubMed](#)
11. Liu Y, *et al.* 2015. *J Immunol.* 194:5851. [PubMed](#)

Product Citations

1. Howson LJ, *et al.* 2018. *Nat Commun.* 9:253. [PubMed](#)
2. Tocheva AS, *et al.* 2020. *Curr Protoc Immunol.* 130:e103. [PubMed](#)
3. Aoki T, *et al.* 2020. *Cancer Sci.* 111:2223. [PubMed](#)
4. Sun A, *et al.* 2021. *J Dent Sci.* 16:751. [PubMed](#)
5. Nakano Y, *et al.* 2017. *PLoS Pathog.* 13:e1006348. [PubMed](#)
6. Hagan T, *et al.* 2020. *Cell.* 178(6):1313-1328.e13. [PubMed](#)
7. Hearnden R, *et al.* 2021. *STAR Protocols.* 2(2):100422. [PubMed](#)
8. Causi E, *et al.* 2015. *PLoS One.* 10: 0136717. [PubMed](#)
9. Palamides P, *et al.* 2016. *Dis Model Mech.* 9: 985 - 997. [PubMed](#)
10. Nixon CC, *et al.* 2020. *Cell Reports Medicine.* 578(7793):160-165. [PubMed](#)
11. Kramer KJ, *et al.* 2022. *Nat Commun.* 13:3466. [PubMed](#)
12. Yamaguchi A, *et al.* 2021. *J Thorac Dis.* 13:5430. [PubMed](#)
13. Hinderer S, *et al.* 2012. *Biomaterials.* 33:5259. [PubMed](#)
14. Beatson RE, *et al.* 2021. *Cell Rep Med.* 2:100473. [PubMed](#)
15. Liu R, *et al.* 2021. *Commun Biol.* 4:652. [PubMed](#)
16. Kreutmair S, *et al.* 2021. *Immunity.* . [PubMed](#)
17. Khanam A, *et al.* 2021. *Front Immunol.* 11:599648. [PubMed](#)
18. Gerstner S, *et al.* 2016. *J Leukoc Biol.* 100(6):1297-1310. [PubMed](#)
19. Ping Y, *et al.* 2020. *Front Cell Dev Biol.* 0.890972222. [PubMed](#)
20. Neff CP *et al.* 2018. *EBioMedicine.* 30:192-202 . [PubMed](#)
21. Phad GE, *et al.* 2022. *Nat Immunol.* 23:1. [PubMed](#)
22. Basar R, *et al.* 2021. *Cell Reports.* 36(3):109432. [PubMed](#)
23. Shen J, *et al.* 2021. *Sci Adv.* 7:eabi9787. [PubMed](#)
24. Lerrer S, *et al.* 2021. *iScience.* 24:103020. [PubMed](#)
25. Stunnenberg M, *et al.* 2021. *Eur J Immunol.* 51:2464. [PubMed](#)
26. Harb H, *et al.* 2021. *Immunity.* 54(6):1186-1199.e7. [PubMed](#)
27. Evans WS, *et al.* 2020. *Exp Physiol.* 105:1408. [PubMed](#)
28. Ohue Y, *et al.* 2014. *Clin Cancer Res.* 20:5052. [PubMed](#)
29. Bradley S, *et al.* 2015. *PLoS One.* 10: 0141171. [PubMed](#)
30. Wang F, *et al.* 2021. *Cell.* 184(2):422-440.e17. [PubMed](#)
31. Pache L, *et al.* 2020. *Cell Rep Med.* 1:100037. [PubMed](#)
32. Vikkurthi R, *et al.* 2022. *Nat Microbiol.* 7:974. [PubMed](#)
33. Su X, *et al.* 2022. *J Transl Med.* 20:378. [PubMed](#)
34. Ni J, *et al.* 2020. *Immunity.* 52(6):1075-1087.e8. [PubMed](#)
35. Kim D, *et al.* 2020. *Nat Med.* 26:236. [PubMed](#)
36. Liu Y, *et al.* 2020. *Methods Mol Biol.* 2111:285. [PubMed](#)
37. Shemesh A, *et al.* 2022. *J Exp Med.* 219:. [PubMed](#)
38. Dhar P, *et al.* 2021. *Commun Biol.* 4:905. [PubMed](#)
39. Duque JSR, *et al.* 2022. *Nat Commun.* 13:3700. [PubMed](#)
40. Harb H, *et al.* 2020. *Nat Immunol.* 1359:21. [PubMed](#)
41. Liu Y, *et al.* 2015. *J Immunol.* 194:5851. [PubMed](#)
42. Sato K, *et al.* 2014. *PLoS Pathog.* 10:1004453. [PubMed](#)
43. Younis R, *et al.* 2016. *J Immunol.* 196: 1419 - 1429. [PubMed](#)
44. Singh KS, *et al.* 2021. *Nature.* 589:597. [PubMed](#)
45. Clayton KL, *et al.* 2021. *Cell Host Microbe.* 29(3):435-447.e9. [PubMed](#)
46. Koh WH, *et al.* 2020. *STAR Protoc.* 1:100203. [PubMed](#)
47. Chakraborty A, *et al.* 2022. *Methods Mol Biol.* 2442:565. [PubMed](#)
48. Olafsdottir TA, *et al.* 2022. *Commun Biol.* 5:914. [PubMed](#)
49. Gladkikh A, *et al.* 2017. *Cancer Med.* . 10.1002/cam4.1257. [PubMed](#)
50. Li M, *et al.* 2020. *Virol Sin.* 35:588. [PubMed](#)
51. Friedensohn S, *et al.* 2018. *Front Immunol.* 9:1401. [PubMed](#)
52. Carrion B, *et al.* 2021. *Neurol Neuroimmunol Neuroinflamm.* 8:. [PubMed](#)
53. Feng Y, *et al.* 2022. *EClinicalMedicine.* 43:101226. [PubMed](#)

RRID

AB_314053 (BioLegend Cat. No. 300317)
 AB_314054 (BioLegend Cat. No. 300318)

Antigen Details

Structure	Ig superfamily, with the subunits of CD3 γ , CD3 δ , CD3 ζ (CD247) and TCR (α/β or γ/δ) forms CD3/TCR complex, 20 kD
Distribution	Mature T and NK-T cells, thymocyte differentiation
Function	Antigen recognition, signal transduction, T cell activation
Ligand/Receptor	Peptide antigen bound to MHC
Cell Type	T cells, NKT cells, Thymocytes, Tregs
Biology Area	Immunology

Molecular Family CD Molecules, TCRs

Antigen References

1. Barclay N, *et al.* 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, *et al.* 1981. *Eur. J. Immunol.* 11:329.
3. Lanier L, *et al.* 1986. *J. Immunol.* 137:2501-2507.

Gene ID [916](#)


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-human CD3, Biotin anti-human CD3, FITC anti-human CD3, PE anti-human CD3, PE/Cyanine5 anti-human CD3, Purified anti-human CD3, APC/Cyanine7 anti-human CD3, PE/Cyanine7 anti-human CD3, Alexa Fluor® 488 anti-human CD3, Alexa Fluor® 647 anti-human CD3, Alexa Fluor® 700 anti-human CD3, PerCP anti-human CD3, PerCP/Cyanine5.5 anti-human CD3, Pacific Blue™ anti-human CD3, Ultra-LEAF™ Purified anti-human CD3, PE/Dazzle™ 594 anti-human CD3

Product Data



Human peripheral blood lymphocytes stained with HIT3a APC/Cyanine7

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587